Studies finds upto 10x more covid19 antibodies in people with Heterologous (mixed) vaccines
studies are coming out now on mixing vaccines in particular viral vector mixed with mrna
came across these studies which confirms the consensus from experts that generally mixing vaccines elicits a better/more robust immune response. These studies look at the antibodies between those with mixed vaccines or same vaccine for the 2 shot regiment
a double course of AZ didn't develop beta antibodies unlike heterogenous mix
https://www.nejm.org/doi/full/10.1056/NEJMc2110716
https://www.medrxiv.org/content/10.1101 ... 21258887v1
came across these studies which confirms the consensus from experts that generally mixing vaccines elicits a better/more robust immune response. These studies look at the antibodies between those with mixed vaccines or same vaccine for the 2 shot regiment
a double course of AZ didn't develop beta antibodies unlike heterogenous mix
https://www.nejm.org/doi/full/10.1056/NEJMc2110716
Here's one comparing Heterogenous vaccines with homogenous mrna vaccinesThe potent induction of SARS-CoV-2 S-specific antibodies after a heterologous boost with mRNA-1273 was reflected by an increase in the in vitro reciprocal serum neutralization titer, with a reciprocal ID50 at 7 to 10 days after the boost that was 20 times as high as that on the day of the boost (P<0.001) (Figure 1A).
In contrast, a homologous ChAdOx1 nCoV-19 boost led to a near doubling of the reciprocal ID50 within 7 to 10 days (P=0.09). At 1 month after the boost, an additional increase in neutralizing antibodies (to levels 1.6 to 1.7 times as high as the levels at 7 to 10 days) occurred in both groups, but the increase was not significant. We verified our results for neutralization of the original SARS-CoV-2 isolate from Sweden in another laboratory (Figure 1B). In addition, we found that an mRNA-1273 boost had induced antibodies that could neutralize the B.1.351 variant of SARS-CoV-2 (Figure 1B); however, a ChAdOx1 nCoV-19 boost did not induce potent neutralizing antibodies against this variant, a finding consistent with findings from a previous study.
https://www.medrxiv.org/content/10.1101 ... 21258887v1
The results were compared to cohorts of healthcare workers or volunteers, who received homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination regimens, respectively. A striking increase of vaccine-induced SARS-CoV-2 neutralizing antibody activity was observed in 229 vaccinees that received a BNT162b2 boost 9 to 12 weeks after ChAdOx1 nCoV-19 prime.
In our cohort comprising over 480 individuals, the heterologous vaccination scheme induced significantly higher neutralizing antibody titers than homologous ChAdOx1 nCoV-19 and even than homologous BNT162b2 vaccination.
This proves that a single dose of a COVID-19 mRNA vaccine after ChAdOx1 nCoV-19 prime vaccination is sufficient to achieve high neutralizing antibody levels predicting immune protection from SARS-CoV-2 infection, and may even increase vaccine efficacy offering an alternative in a setting of vaccine shortage.